Kolexia
Castan Bernard
Maladies infectieuses
Centre Hospitalier de Perigueux
Périgueux, France
85 Activités
541 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladies transmissibles Ecchymose Infections bactériennes Maladie inflammatoire pelvienne Pneumopathie infectieuse COVID-19 Sepsie Dermatoses bactériennes Infections communautaires

Industries

MSD
20 collaboration(s)
Dernière en 2023
ViiV Healthcare
16 collaboration(s)
Dernière en 2022
Gilead
13 collaboration(s)
Dernière en 2023
Sanofi
12 collaboration(s)
Dernière en 2023

Dernières activités

The French medical community united against cuts to State Medical Aid
Health policy (Amsterdam, Netherlands)   01 mai 2024
Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.
Open forum infectious diseases   22 février 2024
Clinical practice recommendations for infectious disease management of diabetic foot infection (DFI) - 2023 SPILF.
Infectious diseases now   10 novembre 2023
Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
The Journal of antimicrobial chemotherapy   21 octobre 2023
Knowledge of recommended antibiotic treatments for community-acquired infections in general medical practice: a cross-sectional study in Occitanie region, France.
Scientific reports   12 octobre 2023
Time to treatment initiation and HIV viral suppression in people diagnosed with HIV-1 during COVID-19 pandemic in ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study).
Journal of acquired immune deficiency syndromes (1999)   28 septembre 2023
Infecciones genitales altas
EMC - Ginecología-Obstetricia   01 septembre 2023
DALICATH: Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
Essai Clinique (Assistance publique – Hôpitaux de Paris)   30 août 2023
Development of an a priori tool to determine the frequency of dalbavancin administrations using a population pharmacokinetic approach
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France   07 juin 2023
Dalbavancin plasma concentrations in 133 patients: A PK-PD observational study
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France   07 juin 2023